Drug Profile
SB 225002
Alternative Names: SB-225002Latest Information Update: 23 Feb 2012
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics; Phenylurea compounds; Small molecules
- Mechanism of Action CXCR receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 01 Jan 2006 Clinical trials in Chronic obstructive pulmonary disease (PO)
- 31 Dec 1999 Preclinical trials in Chronic obstructive pulmonary disease (PO)